


Carfilzomib

Chemical Properties

CAS No. :	868540-17-4
Formula:	C ₄₀ H ₅₇ N ₅ O ₇
Molecular Weight:	719.91
Storage:	Keep away from direct sunlight Powder: -20°C for 3 years <small>Actual storage temperature shall be subject to the COA.</small>



Biological Description

Description	Carfilzomib (PR-171) is a proteasome inhibitor that irreversibly binds to the chymotrypsin of the 20S proteasome. Carfilzomib has antitumor activity and may be used to treat multiple myeloma.
Targets(IC50)	Apoptosis, Proteasome, Autophagy
In vitro	<p>METHODS: Myeloma cell lines RPMI 8226 and ANBL-6 were treated with Carfilzomib (0-25 nM) for 24 h, and cell viability was measured using WST-1 assay.</p> <p>RESULTS: Carfilzomib treatment dose-dependently decreased the cell viability of RPMI 8226 and ANBL-6 cells, with IC50s of less than 5 nM. [1]</p> <p>METHODS: B-cell lymphoma cell lines Raji, Raji-2R and Raji-4RH were treated with Carfilzomib (1-10 nM) for 24-72 h. Apoptosis was analyzed using Flow Cytometry.</p> <p>RESULTS: Carfilzomib induced apoptosis in B-cell lymphoma cell lines and the extent of apoptosis was time dependent. [2]</p>
In vivo	<p>METHODS: To assay anti-tumor activity in vivo, Carfilzomib (5 mg/kg, 10% captisol) was injected intravenously twice weekly for five weeks into SCID mice bearing a mantle cell lymphoma (MCL) Mino.</p> <p>RESULTS: Carfilzomib virtually eliminated tumor growth and significantly prolonged the survival time of the tumor-bearing mice. [3]</p> <p>METHODS: To detect anti-tumor activity in vivo, Carfilzomib (6 mg/kg, 10% captisol) was administered intraperitoneally three times a week for three weeks to a mouse model of metastatic amorphous thyroid tumor (ATC).</p> <p>RESULTS: Carfilzomib treatment of mice with established extensive metastatic disease significantly improved their survival without significant toxicity. [4]</p>
Kinase Assay	Enzyme-linked immunosorbent assay for subunit profiling of carfilzomib: ANBL-6 cells (2 × 10 ⁶ /well) are plated in 96-well plates and treated with Carfilzomib doses from 0.001 to 10 μM for 1 hour. Cells are then lysed (20 mM Tris-HCl, 0.5 mM EDTA), and cleared lysates are transferred to polymerase chain reaction (PCR) plates. A standard curve is generated using untreated ANBL-6 cell lysates starting at a concentration of 6 μg protein/μL. The active site probe [biotin-(CH ₂) ₄ -Leu-Leu-Leu-epoxyketone; 20 μM] is added and incubated at room temperature for 1 hour. Cell lysates are then denatured by adding 1% sodium dodecyl sulfate (SDS) and heating to 100°C, followed by mixing with 20 μL per well streptavidin-sepharose high-performance beads in a 96-well multiscreen DV plate and incubated for 1 hour. These beads are then washed with

Kinase Assay	enzyme-linked immunosorbent assay (ELISA) buffer (PBS, 1% bovine serum albumin, and 0.1% Tween-20), and incubated overnight at 4°C on a plate shaker with antibodies to proteasome subunits. Antibodies used included mouse monoclonal anti-β1, anti-β2, anti-β1i, and anti-β5i, goat polyclonal anti-β2i, and rabbit polyclonal anti-β5 (affinity-purified antiserum against KLH-CWIRVSSDNVADLHDKYS peptide). The beads are washed and incubated for 2 hours with horseradish peroxidase-conjugated secondary goat antirabbit, goat antimouse or rabbit antigot antibodies. After washing, the beads are developed using the supersignal ELISA picochemiluminescence substrate. Luminescent detection is performed. Raw luminescence is converted to µg/mL by comparison with the standard curve and expressed as the % inhibition relative to vehicle control. Curve fits are generated using the following nonsigmoidal dose-response equation: $Y = \text{Bottom} + (\text{Top} - \text{Bottom}) / (1 + 10^{((\text{LogEC50} - X) \times \text{HillSlope}))}$, where X is the logarithm of concentration, Y is the % inhibition, and EC50 is the dose showing 50% effect.
Cell Research	WST-1 is used to determine the effects of proteasome inhibitor Carfilzomib on cell proliferation. The inhibition of proliferation is calculated in relation to parallel control cells that receives vehicle alone. A linear spline function is used to interpolate the median inhibitory concentration (IC50) using XLfit 4 software. The degree of resistance (DOR) is calculated using the formula: $\text{DOR} = \text{IC50}(\text{resistant cells}) / \text{IC50}(\text{sensitive cells})$. ANBL-6 cells pulsed with 100 nM carfilzomib are washed and suspended in PBS containing 5 µg/mL of JC-1, which exhibits potential-dependent accumulation in mitochondria. Analysis of the mitochondrial membrane potential-dependent color shift from 525 to 590 nm is carried out on a FacScan, and the data are analyzed with CellQuest software.(Only for Reference)

Solubility Information

Solubility	Ethanol: < 1 mg/mL (insoluble or slightly soluble), DMSO: 242 mg/mL (336.15 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 5.5 mg/mL (7.64 mM),Suspension. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	1.3891 mL	6.9453 mL	13.8906 mL
5 mM	0.2778 mL	1.3891 mL	2.7781 mL
10 mM	0.1389 mL	0.6945 mL	1.3891 mL
50 mM	0.0278 mL	0.1389 mL	0.2778 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

- Kuhn DJ, et al. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. *Blood*. 2007 Nov 1;110(9):3281-90.
- Zhou Q, Liang J, Yang T, et al. Carfilzomib modulates tumor microenvironment to potentiate immune checkpoint therapy for cancer. *EMBO Molecular Medicine*. 2022 Jan 11;14(1):e14502. doi: 10.15252/emmm.202114502. Epub 2021 Dec 13.
- Gu JJ, et al. The novel proteasome inhibitor carfilzomib induces cell cycle arrest, apoptosis and potentiates the anti-tumour activity of chemotherapy in rituximab-resistant lymphoma. *Br J Haematol*. 2013 Sep;162(5):657-69.
- Kunder R, Velyunskiy M, Dunne S F, et al. Synergistic PIM kinase and proteasome inhibition as a therapeutic strategy for MYC-overexpressing triple-negative breast cancer. *Cell Chemical Biology*. 2021
- Qu X, Liu H, Song X, et al. Effective degradation of EGFR L858R+ T790M mutant proteins by CRBN-based PROTACs through both proteasome and autophagy/lysosome degradation systems. *European Journal of Medicinal Chemistry*. 2021, 218: 113328.
- Zhang L, Pet al. In vitro and in vivo therapeutic efficacy of carfilzomib in mantle cell lymphoma: targeting the immunoproteasome. *Mol Cancer Ther*. 2013 Nov;12(11):2494-504.
- Mehta A, et al. Carfilzomib is an effective anticancer agent in anaplastic thyroid cancer. *Endocr Relat Cancer*. 2015 Jun;22(3):319-29.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481